knowledge -WSS

knowledge

author：hotspot 2025-09-28 07:21:47 - browse：7974

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Nobel honors Karikó and Weissman's enduring partnership

hotspot

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Roche to buy Carmot Therapeutics, developer of obesity drugs

Some top drug companies are starting to take action on climate

WHO recommends second malaria vaccine

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

6 solutions to address cancer drug shortages and others

hotspot

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

What we owe ALS patients — and why one company fell short

Wildfire smoke exposes gaps in outdoor worker protections

In diabetes hearing, Sanders takes on a new foe: food makers

After affirmative action ruling, medical educators look to 'holistic review'

The woman behind the Dana Farber

Drug repurposing or repositioning? The language matters

With Roe v Wade overturned, abortion providers work to adapt

Guidelines to prevent youth baseball injuries need more muscle

Pfizer plans to depart BIO

Wikipedia

STAT letters to the editor on burnt

The Karikó problem: Lessons for funding basic research

STAT letters to the editor on burnt

Lawsuit highlights wrinkle for disputes over surprise medical bills

Experts study whether long Covid risk adds up with each reinfection

Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

Wikipedia

hotspot

Wikipedia